Rick, as some said trading next Monday (and possibly Tuesday) will be a big tell for future PPS direction for CLRB. If this stock has another big day, which I think it will, then a multitude of traders on Wall Street and Main Street will certainly have a closer look at this stock throughout the week. According to Google Finance, CLRB is owned by 30% of institutional investors who will certainly be actively trading this stock on the volume and price side to get further PPS traction on Monday.
When this happens Wall Street brokers and analysts will surely reach out to their bio-pharma friends and contacts in the industry to get further insight on CLRB oncology/cancer delivery technology as well as orphan drugs in their pipe line. If they like what they hear then they will quickly get a buyout deal going. I mean look at the current market cap for this oncology-cancer company? $13.2 million, it's so ridiculously LOW! The young guns on Wall Street will want to make a name for themselves, and brokering a deal between CLRB and big pharma might be the big ticket for them.
News 
Market Data 
Discover 
